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Chronic granulomatous disease (CGD) is an uncommon inherited 
disorder caused by mutations in any of the genes encoding 
subunits of the superoxide-generating phagocyte NADPH oxidase 
system, which is essential for killing catalase producing bacteria 
and fungi, such as Aspergillus species, Staphylococcus aureus, 
Serratia marcescens, Nocardia species and Burkholderia cepacia. 
In case of a history of recurrent or persistent infections, immune 
deficiency should be investigated. Particularly, in the case of 
uncommon infections such as aspergillosis in early life, CGD should 
be considered. We describe here a case of CGD that presented 
with invasive pulmonary aspergillosis in a 2-month-old girl. We 
confirmed pulmonary aspergillosis noninva  sively through a positive 
result from the culture of bronchial alveolar lavage fluid, positive 
serological test for Aspergillus antigen and radiology results. She 
was successfully treated with Amphotericin B and recombinant 
IFN-γ initially. Six weeks later after discharge, she was readmitted 
for pneumonia. Since there were infiltrates on the right lower lung, 
which were considered as residual lesions, voriconazole therapy 
was initiated. She showed a favorable response to the treatment and 
follow-up CT showed regression of the pulmonary infiltrates.
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Introduction
Chronic granulomatous disease (CGD) is a group of rare 
X-linked or autosomal recessive genetic disorders of the phagocytic 
NADPH oxidase system causing recurrent bacterial and fungal 
infections with excessive inflammation and granuloma formation
1, 
2). Granuloma formation is considered to occur secondary to the 
failure of phagocytes in killing bacteria and due to undigested 
intracellular bacterial debris
3).
CGD is normally diagnosed in infancy and has an incidence 
of 1 in 200,000-250,000 live births
4, 5). Most patients manifest 
symptoms and signs of recurrent and persistent infections during 
the first 2 years of life. The disorder is much more common in 
males than in females, with 86% of patients in the USA national 
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registry being male
5). It has a mortality of approximately 2% per 
year, with a predicted life expectancy of around 25-30 years. 
In this article, we describe an unusual case of aspergillus 
fumigatus pneumonia in a 2-month-old girl with CGD who 
showed a favorable response to treatment with amphotericin B and 
recombinant IFN-γ (r IFN-γ).
Case report
A 2 months old girl, born at a gestational age of 38+2 weeks was 
referred to us for investigations regarding persistent pneumonia. 
The girl suffered from several episodes of recurrent infections 
such as neonatal sepsis and gastroenteritis, since the 6
th day of her 
life at the time of admission, she had received three recent course 
of antibiotics from the previous hospital including cefepime, 
clindamycin and imipenem due to persistent pneumonia. On 
admission, physical examination revealed mild chest retraction 
and rales in both lung fields. She was alert and responsive, with no 
neurological deficit. Her height and weight were at the 25
th-50
th 
percentile and the 50
th-75
th percentile for her age respectively.
A chest X-ray (Fig. 1) confirmed the presence of bilateral 
pulmonary consolidation and atelectasis. Diagnostic broncho-
alveolar lavage (BAL) was performed to obtain specimens for 
cytology and culture. A computed tomography (CT) of the thorax 
showed a left sided consolidation and evidence of hematogenously 
disseminated multifocal pneumonia.
She had no family history related to primary immunodeficiency.
Her total leucocyte count was 10,500/μL, with 34% neutrophils 
and 52% lymphocytes. The ESR was 12 mm/hr, and CRP 
3.54 mg/dL. Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels were raised (174 IU/L and 398 IU/
L, respectively). Electrolyte levels and the results of renal function 
tests were normal. Investigations for her immunologic work-up 
showed Ig G, Ig A, Ig M, Ig E, C3, C4, and CH50 levels to be 
Fig. 1. Pulmonary infection in a 2-month-old patient with CGD who presented with Aspergillus pneumonia. 
Bilateral pneumonic infiltrates on X-ray A) and multifocal consolidations in the left lung field on CT scanning 
B) are observed. Follow-up CT scan obtained 4 weeks later shows a decrease volume of consolidation, 
especially on the left lower field C).
A
B
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Fig. 2. The NBT test in the CGD patient and normal control. A) The negative NBT test in this CGD patient, B) A 
normal NBT test in a control.
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within her age specific reference range. Lymphocyte subset analysis 
revealed normal B cells and T cells for her age. Diagnosis of CGD 
was confirmed by both abnormal neutrophil nitroblue tetrazolium 
(NBT) slide test (Fig. 2) and neutrophil respiratory burst activity 
test (Fig. 3 B-1, B-2). The detection of Aspergillus galactomannan 
antigenemia during onceweekly monitoring was performed to 
facilitate early diagnosis of invasive aspergillosis and to evaluate the 
response to the antifungal therapy (amphotericin B). The course of 
the Aspergillus antigen galactomannan titer in the serum during 
treatment is shown in Fig. 4. A genetic study for the mutation of 
the NCF1 (Neutrophil cytosol factor 1) gene encoding the p47
phox 
the most common gene mutation in autosomal recessive CGD, 
was done, but the mutation was not found.
After a positive result from BAL culture and Aspergillus antigen 
detection, an antifungal agent was added to the treatment. 
Amphotericin B therapy was initiated at a dose of 0.25 mg/kg/
d, followed by a daily dosage increases of 0.25 mg/kg/d until 
a therapeutic dosage (1.0 mg/kg/d) was reached. However, the 
NBT dye reduction test revealed absolutely no reduction of dye by 
neutrophils therefore INF-γ administered subcutaneously at a dose 
of 15 μg three times weekly was added to the patient’s regimen.
During the treatment for Aspergillus pneumonia, we found 
right-sided inguinal lymphadenopathy, at the previous central line 
insertion site, a subsequent culture yielded Enterobacter aerogenes. 
Perianal fissures had also occurred, and we therefore had the 
patient soak in a shallow tub of warm water (sitz bath). During 
the admission period, her AST and ALT levels rose significantly. 
We performed hepatitis serology and abdominal ultrasonography 
several times to identify the cause of the elevated liver enzymes. All 
tests produced normal results. We considered antibiotics-induced 
toxicity or the natural course of the disease as possible causes. We 
had added voriconazole to her regimen because of the residual 
lesions on the lung. However, during voriconazole administration, 
abnormal liver function values appeared, therefore we stopped 
voriconazole therapy.
At the time of discharge from our center, which was 3 months 
after admission, her acute phase inflammatory markers and 
Aspergillus precipitins had all progressively returned to normal. 
A chest radiograph and CT scan after a 3-month course of 
antifungal treatment with IFN-γ showed complete resolution 
of the previous findings. BAL culture and a serological test were 
both negative. However, six weeks after the discharge, she was 
readmitted with fever due to recurrent pneumonia, considered as 
a previous remnant lesion. She was treated with voriconazole for 4 
weeks and commenced on prophylactic antibiotics and antifungal 
agents. We are currently considering HLA-identical bone marrow 
transplantation (BMT) for this patient at the age of 1- year-old.
Discussion
CGD is a primary immunodeficiency disorder characterized 
by defects in superoxide-generating systems of phagocytes leading 
to recurrent bacterial and fungal infections. Diagnosis of this 
disease requires a high index of suspicion along with prompt 
and aggressive treatment of infections. The presentation of this 
patient with recurrent, uncommon infections in early infanthood 
pointed towards a primary immunodeficiency. The patterns of 
presentation differ from patient to patient in CGD. As shown in 
this case, the lung is the most common site of infection, manifested 
as pneumonia or pulmonary abscess. Alternatively, dermatitis, 
subcutaneous abscess, lymphadenitis, liver abscess or osteomyelitis 
may be the prominent clinical problem in CGD patients
7).
The diagnosis of CGD is confirmed by the NBT dye reduction 
Fig. 3. The result of the neutrophil burst activity test in the 2-month-old 
patient with CGD. In contrast to the control on the left side (A-1, A-2), there 
were defects with a right sided shift and a fluorescence peak of low intensity 
in this patient (B-1, B-2).
Fig. 4. The course of the Aspergillus antigen galactomannan titer in the 
serum during treatment with Amphotericin-B. The titer remained high during 
treatment with amphotericin B initially but started to decline 5 weeks after 
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test and the respiratory burst activity test. Normally the percentage 
of blue-stained neutrophils is close to 100, but in CGD patients, 
this percentage is close to 0. In this case, the neutrophil respiratory 
burst activity test showed a dual population in the mother of the 
patient, further her father’s neutrophil respiratory burst activities 
were slightly decreased, which suggested an autosomal recessive 
inheritance pattern.
In CGD patients, neutrophils are able to phagocytose particles 
normally, but are unable to generate superoxide anions that are 
essential for microbial killing. The degree of superoxide anion 
production is determined partially according to the type of the 
inheritance pattern
2). Therefore the functional and molecular 
diagnosis of CGD may be useful for predicting the prognosis 
and deciding the appropriate treatment. For example, there are 
several subtypes in gp91phox mutations, which are inherited in 
the pattern of X-linked form. In the X91
0, which accounting for 
approximately 90% of the X-linked CGD cases, NADPH oxidase 
activity is totally abolished because of both the instability of the 
mRNA and protein. X91
- , accounting for less than 10% cases 
among the X-linked mutations, is a type of promoter mutation 
that causes 3-9% of normal NADPH oxidase activity, resulting in 
later diagnosis and a milder clinical course than X91
0. Autosomal 
recessive CGD, accounting for about 30-40% of all CGD cases is 
caused by the genetic defects in one of the p47phox, p67phox and 
p22phox.
The microorganisms responsible for the majority of infections 
in CGD are S. aureus, Gram-negative enteric bacilli (including 
Serratia marcescens, Salmonella species, and Burkholderia 
cepacia), and Aspergillus species. Aspergillus fumigatus infection 
as shown in this case, accounts for 15% of infections in CGD 
patients. It appears to occur because of the failure to clear hyphae 
by neutrophils’ oxidant mechanisms. Further the defect in 
phagocytes’ oxidant production is associated with a prolonged 
inflammatory response, causing granuloma formation
3). The 
diagnosis of aspergillosis in CGD is difficult and important. In 
this case, we used noninvasive tests such as BAL culture and 
Aspergillus antigen detection without an invasive procedure such 
as lung tissue biopsy. Bronchoscopy with BAL is an established 
method for the diagnosis of pulmonary infections, especially in 
immunocompromised patients
8). In a study, the diagnostic value 
sensitivity of bronchoscopy is 43% in the cases of histologically 
proven invasive pulmonary aspergillosis
9). The Aspergillus 
galactomannan antigenemia assay may assist in the diagnosis of 
aspergillosis with a sensitivity of 81% and a specificity of 89%
10).
Further, when amphotericin B is being used in therapy, 
falsenegative results may occur because the antifungal agent 
suppresses the growth of hyphae
9). We monitored the antigenemia 
during once-weekly and observed declining values, suggesting 
successful treatment.
The management of CGD patients includes avoidance of 
infection with prophylactic antibiotic therapy and aggressive 
treatment of acute infections and inflammatory complications. In 
a randomized, non-blinded trial comparing voriconazole versus 
amphotericin B in the treatment of invasive aspergillosis, successful 
outcomes were noted in 52.8% of the patients in the voriconazole 
group and 31.6% of those in the amphotericin B group
11). In our 
case, therapy with voriconazole during the first admission period 
had to be discontinued because of liver toxicity. When voriconazole 
was administered during the second admission period, it proved 
very effective and was well tolerated. 
IFN-γ prophylaxis reduces the frequency of the serious infections 
by 70% by increasing the production of superoxides in CGD 
patients. Stem cell transplantation is curative in CGD
9). Even 
in patients with active Aspergillus infection, human leukocyte 
antigen (HLA)-identical BMT or peripheral blood stem cell 
transplantation has been successfully performed with granulocyte-
colony stimulating factor (G-CSF)-mobilized granulocyte 
transfusions
10, 12). However in the absence of an HLA-identical 
family donor, BMT or peripheral blood stem cell transplantation 
is not recommended
9). A therapeutic alternative for CGD patients 
with no HLA-identical donors is the genetic modification of 
autologous hematopoietic stem cells (HSC)
13). Although CGD 
has been successfully corrected in animal models by gene transfer 
in HSCs, similar success have been achieved in humans with 
CGD. In this report, substantial gene transfer in CGD patients’ 
neutrophils lead to a large number of functionally corrected 
phagocytes and notable clinical improvement
13).
References
  1)  Perfect JR, Savani DV, Durack DT. Uptake of itraconazole by alveolar 
macrophages. Antimicrob Agents Chemother 1993;37:903-4.
 2)  Stasia MJ, Li XJ. Genetics and immunopathology of chronic 
granulomatous disease. Semin Immunopathol 2008;30:209-35.
 3)  Levine S, Smith VV, Malone M, Sebire NJ. Histopathological features 
of chronic granulomatous disease (CGD) in childhood. Histopathology 
2005;47:508-16.
 4)  Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. 
Curr Opin Immunol 2003;15:578-84.
 5)  Winkelstein JA, Marino MC, Johnston RB, Jr., Boyle J, Curnutte J, 
Gallin JI, et al. Chronic granulomatous disease. Report on a national 
registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
 6)  Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, 
et al. Clinical features, long-term follow-up and outcome of a large cohort 726      E Lee, et al. • A case of CGD presenting with aspergillus pneumonia in an infant
of patients with Chronic Granulomatous Disease: an Italian multicenter 
study. Clin Immunol 2008;126:155-64.
 7)  Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by 
defects in phagocytes. N Engl J Med 2000;343:1703-14.
 8)  Reichenberger F, Habicht J, Matt P, Frei R, Soler M, Bolliger CT, et 
al. Diagnostic yield of bronchoscopy in histologically proven invasive 
pulmonary aspergillosis. Bone Marrow Transplant 1999;24:1195-9.
 9)  Bielorai B, Toren A, Wolach B, Mandel M, Golan H, Neumann Y, et al. 
Successful treatment of invasive aspergillosis in chronic granulomatous 
disease by granulocyte transfusions followed by peripheral blood stem 
cell transplantation. Bone Marrow Transplant 2000;26:1025-8.
10)  Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. 
Transpl Infect Dis 2003;5:158-66.
11)   Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, 
Oestmann JW, et  al. Voriconazole versus amphotericin B for primary 
therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
12)  Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, et 
al. Successful treatment of invasive aspergillosis in chronic granulomatous 
disease by bone marrow transplantation, granulocyte colony-stimulating 
factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 
1998;92:2719-24.
13)  Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U,et al. 
Correction of X-linked chronic granulomatous disease by gene therapy, 
augmented by insertional activation of MDS1-EVI1,PRDM16 or 
SETBP1. Nat Med 2006;12:401-9. 